AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Nexalin Technology shares rise 10.19% premarket after promising results in Gambling Disorder treatment trial.
ByAinvest
Tuesday, Nov 18, 2025 9:16 am ET1min read
Nexalin Technology surged 10.19% in premarket trading following the release of promising clinical results for its 15 mA neurostimulation device in treating gambling disorder with comorbid alcohol use, announced 16 minutes prior. The data, published by GlobeNewswire, highlight the device’s potential to address a significant unmet medical need, bolstering investor confidence ahead of the stock’s opening. While other recent developments, such as regulatory approvals in Israel and Alzheimer’s-related updates, occurred weeks earlier, the immediate premarket rally aligns with the latest clinical trial outcome, underscoring market optimism about the device’s therapeutic applications and commercial prospects.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet